Joseph Thome
Stock Analyst at TD Cowen
(0.20)
# 4,127
Out of 4,829 analysts
18
Total ratings
20%
Success rate
-33.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $13.11 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $310.80 | +28.70% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $10.46 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $31.26 | +8.78% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $1.35 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.55 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $46.01 | -34.80% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $4.07 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $35.85 | - | 1 | Dec 12, 2022 | |
| ACRV Acrivon Therapeutics | Initiates: Outperform | n/a | $1.20 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.17 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $110.16 | +18.01% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.55 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.82 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.33 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $13.11
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $310.80
Upside: +28.70%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $10.46
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $31.26
Upside: +8.78%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $1.35
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $46.01
Upside: -34.80%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.07
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $35.85
Upside: -
Acrivon Therapeutics
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.17
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $110.16
Upside: +18.01%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.55
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.82
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.33
Upside: -